SAN ANTONIO (Reuters Health) - Letrozole is more effective than tamoxifen as an initial hormone therapy in postmenopausal women with hormone-sensitive, early breast cancer, researchers announced here ...

The study by Regan and colleagues presents an update on efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8.1 years median follow-up. BIG 1-98 is a randomized, phase 3, ...

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial This report ...

Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and ...

The Breast International Group (BIG) 1-98 study evaluated adjuvant endocrine therapy in postmenopausal women who had hormone receptor-positive early-stage breast cancer. The study participants were ...

Please provide your email address to receive an email when new articles are posted on . Use of an aromatase inhibitor instead of tamoxifen reduced the risk for breast cancer recurrence among ...

Duke researchers claim that the breast cancer drug Femara works better than Tamoxifen. In a study of postmenopausal women with estrogen-positive tumors, 60 percent of the women taking Femara showed ...

CHICAGO (Reuters) - Taking the breast cancer pill Femara can significantly reduce the chances that a woman's cancer will return, even long after she has stopped taking the estrogen blocker tamoxifen, ...

Femara reduced the risk of breast cancer recurrence by an additional 21 percent over the reduction offered by tamoxifen. Also, the study showed, patients taking Femara showed a 27 percent reduction in ...

Switzerland’s Novartis has received a boost following the news that Germany, via the European mutual recognition procedure, has become the first country to grant marketing authorisation for the firm’s ...